Keeping Track: FDA Approves Novel HIV Treatment, New Dosing Regimen For Opdivo; Another Rare Pediatric Disease Designation For Prometic

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your US review and approval news in brief: For the first time in a decade, a drugmaker has scored an approval for an HIV treatment with a new mechanism of action, with TaiMed Biologics Inc. winning the US FDA's blessing for the CD4-directed post-attachment HIV-1 inhibitor Trogarzo (ibalizumab-uiyk).

Bristol-Myers Squibb Co.landed a newly approved dosing regimen for Opdivo (nivolumab), as the drugmaker seeks to separate its PD-1...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet